

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**206073Orig1s000**

**CLINICAL PHARMACOLOGY AND  
BIOPHARMACEUTICS REVIEW(S)**

**BIOPHARMACEUTICS REVIEW ADDENDUM**  
**Office of New Drug Quality Assessment**

<b>Application No.:</b>	NDA 206-073	<b>Reviewer:</b> Kareen Riviere, Ph.D.	
<b>Submission Date(s):</b>	1/30/14; 6/3/14		
<b>Division:</b>	DMEP	<b>Secondary Signature:</b> Tapash Ghosh, Ph.D.	
<b>Applicant:</b>	Boehringer Ingelheim Pharmaceuticals, Inc.	<b>Supervisor:</b> Paul Seo, Ph.D.	
<b>Trade Name:</b>	Glyxambi	<b>Date Assigned:</b>	1/30/14
<b>Generic Name:</b>	empagliflozin/linagliptin fixed-dose combination tablets	<b>Date of Review:</b>	10/15/14
<b>Indication:</b>	adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	<b>Type of Submission:</b> 505(b)(1) New Drug Application	
<b>Formulation/strengths:</b>	IR Tablet; 10 mg/5 mg and 25 mg/5mg		
<b>Route of Administration:</b>	Oral		

In the Biopharmaceutics review dated September 16, 2014, Dr. Kareen Riviere stated that Glyxambi (empagliflozin/linagliptin) 10 mg/5 mg and 25 mg/5mg immediate release tablets are recommended for approval from a Biopharmaceutics standpoint pending the OSI inspection results for the pivotal BE Study 1275.3. In the OSI inspection report for Study 1275.3 dated October 3, 2014, Drs. Seongeun (Julia) Cho and Sripal R. Mada stated:

*Based on the inspectional outcomes, these reviewers conclude that the clinical and analytical portions of the Study 1275.003 are acceptable for further Agency review.*

Thus, NDA 206-073 for Glyxambi (empagliflozin/linagliptin) 10 mg/5 mg and 25 mg/5mg immediate release tablets is recommended for approval from the Biopharmaceutics perspective.

**Kareen Riviere, Ph.D.**  
 Biopharmaceutics Reviewer  
 Office of New Drug Quality Assessment

**Tapash Ghosh, Ph.D.**  
 Biopharmaceutics Team Leader  
 Office of New Drug Quality Assessment

cc: Dr. Paul Seo

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

KAREEN RIVIERE  
10/15/2014

TAPASH K GHOSH  
10/15/2014

## OFFICE OF CLINICAL PHARMACOLOGY REVIEW

<b>NDA:</b>	206073
<b>Submission Date(s):</b>	January 30, 2014
<b>Brand Name</b>	Glyxambi
<b>Generic Name</b>	Empagliflozin / Linagliptin FDC
<b>OCP Division</b>	Clinical Pharmacology -2
<b>OND division</b>	Metabolism and Endocrinology Products
<b>Sponsor</b>	Boehringer Ingelheim Pharmaceuticals, Inc.
<b>Submission Type; Code</b>	NDA 505(b)(1); Standard
<b>Formulation; Strength(s)</b>	Tablets: <ul style="list-style-type: none"> <li>• 10 mg empagliflozin/5 mg linagliptin</li> <li>• 25 mg empagliflozin/5 mg linagliptin</li> </ul>
<b>Proposed Indication</b>	<ul style="list-style-type: none"> <li>• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when both empagliflozin and linagliptin is appropriate.</li> </ul>
<b>Dosage &amp; Administration</b>	<ul style="list-style-type: none"> <li>• The recommended starting dose of Glyxambi is 10 mg empagliflozin/5 mg linagliptin once daily.</li> <li>• Dose can be increased to 25 mg empagliflozin/5 mg linagliptin once daily in patients who require additional glycemic control.</li> <li>• Glyxambi can be taken with or without food.</li> <li>• Do not initiate Glyxambi if eGFR is below 45 mL/min/1.73 m<sup>2</sup></li> </ul>
<b>Clinical Pharmacology Reviewer</b>	Suryanarayana Sista, PhD
<b>Clinical Pharmacology Team Leader (Acting)</b>	Manoj Khurana, PhD

## TABLE OF CONTENTS

1	Executive Summary .....	5
1.1	Recommendation .....	5
1.2	Phase IV Commitments.....	5
1.3	Summary of Important Clinical Pharmacology Findings .....	5
2	Question-Based Review (QBR).....	6
2.1	What are the in vivo Clinical Pharmacology and Biopharmaceutics studies with PK information submitted in the NDA.....	6
2.1.1	What are the highlights of the Glyxambi drug product as they relate to clinical pharmacology review?.....	9
2.1.2	What is the composition of to-be-marketed formulation of Glyxambi? .....	9
2.1.3	What are the proposed mechanism of action and therapeutic indications?.....	10
2.1.4	What are the proposed dosages and routes of administration? .....	12
2.2	General Clinical Pharmacology .....	12
2.2.1	What is known about the PK characteristics of Empagliflozin and Linagliptin following the administration of approved drugs, Jardiance and Tradjenta tablets? .....	12
2.2.2	Were the active moieties in the plasma appropriately identified and measured to assess the pharmacokinetics?.....	13
2.3	Intrinsic Factors.....	14
2.3.1	What intrinsic factors (e.g., weight, gender, race, age, height, disease, genetic polymorphism, pregnancy, and organ dysfunction) influence exposure (PK usually) and/or response, and what is the impact of any differences in exposure on efficacy or safety responses?.....	14
2.4	Extrinsic Factors .....	14
2.4.1	What extrinsic factors (drugs, herbal products, diet, smoking, and alcohol use) influence exposure and/or response and what is the impact of any differences in exposure on pharmacodynamics?.....	14
2.5	General Biopharmaceutics .....	14
2.5.1	Was bioequivalence established between Empagliflozin and Linagliptin FDC formulations and individual components?.....	14
2.5.2	What is the effect of food on the bioavailability of Empagliflozin and Linagliptin from the FDC.....	15
2.5.3	How did the systemic exposure of empagliflozin and linagliptin from FDA compare to the individual treatment in the Phase III program?.....	21
2.6	Exposure Response .....	23
2.6.1	Is there an exposure-response (e.g. dose-response, concentration-response) relationship for effectiveness and safety for empagliflozin/linagliptin FDC in T2DM patients?23	
2.7	Analytical.....	27
2.7.1	Is the analytical method for Empagliflozin and Linagliptin appropriately validated? .....	27
3	Labeling Comments (Preliminary) .....	29
4	APPENDIX.....	38
	OCP Filing Memo .....	38
	General Information About the Submission .....	39

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.